SciELO - Scientific Electronic Library Online

 
vol.61First report of an autochthonous human visceral leishmaniasis in a child from the South of Minas Gerais State, BrazilMurine typhus in Mexico City: report of an imported case author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

Share


Revista do Instituto de Medicina Tropical de São Paulo

On-line version ISSN 1678-9946

Abstract

MUCENIC, Marcos et al. Sofosbuvir, ribavirin and pegylated interferon for a daclatasvir-resistent genotype 3 hepatitis C virus: case report and review. Rev. Inst. Med. trop. S. Paulo [online]. 2019, vol.61, e12.  Epub Feb 14, 2019. ISSN 1678-9946.  http://dx.doi.org/10.1590/s1678-9946201961012.

Chronic Hepatitis C relapse after liver transplantation can lead to graft failure within a short time period. The high efficacy and good safety profile of direct-acting antivirals has led to consensual recommendations for using interferon-free treatment after liver transplantation. However, pegylated interferon may still be required for genotype 3 non-responders. We treated a liver graft recipient with grade 1 fibrosis in the biopsy with daclatasvir and sofosbuvir for 12 weeks. He did not respond and progressed to grade 3 fibrosis. Lacking other options, we obtained a sustained virological response with pegylated interferon, ribavirin and sofosbuvir for 12 weeks. The combination of pegylated interferon, ribavirin and sofosbuvir is a viable option after the failure of direct acting antivirals in economically disadvantaged countries.

Keywords : Hepatitis C virus; Liver transplantation; Treatment.

        · text in English     · English ( pdf )